Robert Nachbar, PhD

Wolfram Research, Inc.

Disclosure(s): Merck & Co., Inc.: Stocks/Bonds (Public Company), US 7,219,020, US 5,292,741, Vendor

Poster(s):

• (P-11) Assessing the Epidemiological Impact of an Age-Based Pneumococcal Vaccine Recommendation in France
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-12) Evaluating the Epidemiological Impact of Lowering the Recommended Age for Adult Pneumococcal Vaccination in the United States
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-52) Modeling the Epidemiological Impact of Different Adult Vaccination Strategies in the United Kingdom
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-58) Quantifying the impact of introducing a new adult-focused PCV in the United States
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT